Table 2.
Characteristics of the study populations.
| Czech Republic | Austria | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | Controls | Cases | OR | 95% CI | p-Value | Controls | Cases | OR | 95% CI | p-Value | |
| No. (%) | No. (%) | No. (%) | No. (%) | ||||||||
| Sex | Female | 478 (40.8) | 696 (38.1) | Ref | 353 (43.1) | 389 (40.9) | Ref | ||||
| Male | 694 (59.2) | 1133 (61.9) | 1.20 | 1.02–1.40 | 0.03 | 467 (56.9) | 561 (59.1) | 1.39 | 1.09–1.78 | 0.01 | |
| Age (years) | <50 | 269 (22.9) | 140 (9.2) | Ref | 92 (11.2) | 129 (13.5) | Ref | ||||
| (50, 60] | 546 (46.6) | 433 (28.4) | 1.52 | 1.20–1.94 | 0.0006 | 147 (17.9) | 208 (21.9) | 2.18 | 0.72–1.43 | 0.92 | |
| (60, 70] | 183 (15.6) | 639 (42.0) | 6.71 | 5.16–8.72 | <0.0001 | 282 (34.4) | 323 (34.0) | 0.82 | 0.60–1.13 | 0.22 | |
| >70 | 174 (14.9) | 310 (20.4) | 3.42 | 2.60–4.51 | <0.0001 | 299 (36.5) | 291 (30.6) | 0.70 | 0.51–0.96 | 0.03 | |
| BMI | (18.5, 25] | 93 (8.0) | 358 (23.5) | Ref | 189 (23.7) | 296 (35.7) | Ref | ||||
| <18.5 | 334 (28.5) | 370 (24.3) | 3.22 | 2.45–4.24 | <0.0001 | 2 (0.3) | 17 (2.0) | 5.43 | 1.24–23.76 | 0.02 | |
| (25, 30] | 529 (45.1) | 508 (33.4) | 0.84 | 0.69–1.02 | 0.08 | 364 (45.6) | 336 (40.5) | 0.59 | 0.47–0.75 | <0.0001 | |
| >30 | 213 (18.4) | 286 (18.8) | 1.13 | 0.89–1.43 | 0.31 | 243 (30.4) | 181 (21.8) | 0.48 | 0.37–0.62 | <0.0001 | |
| Smoking habit | No | 638 (57.6) | 769 (53.1) | Ref | 447 (55.7) | 251 (48.8) | Ref | ||||
| Yes a | 470 (42.4) | 679 (46.9) | 1.33 | 1.13–1.56 | <0.001 | 356 (44.3) | 263 (51.2) | 1.30 | 0.97–1.73 | 0.08 | |
| DM | No | 555 (85.5) | 1076 (80.4) | Ref | 370 (82.8) | 817 (86.0) | Ref | ||||
| Yes | 94 (14.5) | 263 (19.6) | 1.41 | 1.09–1.84 | 0.01 | 77 (17.2) | 133 (14.0) | 0.62 | 0.42–0.92 | 0.02 | |
| Family history of CRC | No | 942 (89.3) | 1103 (84.1) | Ref | NDA | NDA | |||||
| Yes | 113 (10.7) | 209 (15.9) | 1.65 | 1.28–2.12 | <0.001 | NDA | NDA | ||||
| Diagnosis | Colon | 1192 (65.8) | 586 (62.6) | ||||||||
| Rektum | 621 (34.2) | 350 (37.4) | |||||||||
| tnm stage | I | 277 (16.8) | 188 (21.2) | ||||||||
| II | 498 (30.2) | 227 (25.5) | |||||||||
| III | 491 (29.8) | 354 (39.8) | |||||||||
| IV | 384 (23.3) | 120 (13.5) | |||||||||
| Chemotherapy | None | 795 (49.9) | 389 (43.0) | ||||||||
| 5-FU | 494 (31.0) | 253 (28.0) | |||||||||
| 5-FU combined with oxaliplatin | 303 (19.1) | 262 (29.0) | |||||||||
OR—odds ratio; CI—confidence interval; BMI—body mass index; DM—diabetes mellitus; CRC—colorectal cancer; TNM—tumor-node-metastasis; 5-FU—5-fluorouracil; NDA—no data available. Significant results are in bold. Numbers may not add up to 100% of available subjects because of missing data. a Ex-smokers included in smokers.